Anúncio
Anúncio

LAB

LAB logo

Standard BioTools Inc. Common Stock

1.27
USD
Patrocinado
+0.02
+2.00%
31 de dez., 15:18 UTC -5
Encerrado
exchange

Pós-Mercado

1.28

0.00
+0.31%

Relatórios de Lucros LAB

Rácio de surpresa positiva

LAB separação 15 de 34 últimas estimativas.

44%

Próximo Relatório

Data do Próximo Relatório
24 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$18.68M
/
-$0.07
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-4.43%
/
-22.22%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-60.00%
/
-22.22%

Standard BioTools Inc. Common Stock earnings per share and revenue

On 04 de nov. de 2025, LAB reported earnings of -0.09 USD per share (EPS) for Q3 25, missing the estimate of -0.05 USD, resulting in a -61.87% surprise. Revenue reached 19.55 milhão, compared to an expected 18.18 milhão, with a 7.56% difference. The market reacted with a -4.20% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -0.07 USD, with revenue projected to reach 18.68 milhão USD, implying an diminuir of -22.22% EPS, and diminuir of -4.43% in Revenue from the last quarter.
FAQ
For Q3 2025, Standard BioTools Inc. Common Stock reported EPS of -$0.09, missing estimates by -61.87%, and revenue of $19.55M, 7.56% above expectations.
The stock price moved down -4.2%, changed from $1.19 before the earnings release to $1.14 the day after.
The next earning report is scheduled for 24 de fev. de 2026.
Based on 4 analistas, Standard BioTools Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $18.68M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio